Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -483.37% is 35% above its 5-year average of -742.42%, near the high end of its 5-year range (-13074.39%–804.55%).
49.96% above its 12-month average of -965.92%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -3146.83%.
EBITDA MARGIN
-483.37%
EBITDA MARGIN AVG TTM
-965.92%
EBITDA MARGIN AVG 3Y
-249.26%
EBITDA MARGIN AVG 5Y
-742.42%
EBITDA MARGIN AVG 10Y
-1350.20%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+49.96%
CURRENT VS 3Y AVG
-93.92%
CURRENT VS 5Y AVG
+34.89%
CURRENT VS 10Y AVG
+64.20%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Wave Life Sciences Ltd.
Market Cap
$693.61M
EBITDA Margin
-483.37%
TTM Avg
-965.92%
3Y Avg
-249.26%
5Y Avg
-742.42%
Market Cap
$694.79M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
Market Cap
$685.49M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
Market Cap
$681.27M
EBITDA Margin
-1285.45%
TTM Avg
-897.10%
3Y Avg
-897.10%
5Y Avg
-897.10%
Market Cap
$681.02M
EBITDA Margin
-547.98%
TTM Avg
-848.64%
3Y Avg
-1500.78%
5Y Avg
-1508.87%
Market Cap
$709.65M
EBITDA Margin
52.93%
TTM Avg
53.31%
3Y Avg
49.89%
5Y Avg
44.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Wave Life Sciences Ltd. (WVE) | $693.61M | -483.37% | -965.92% | -249.26% | -742.42% |
| Faeth Therapeutics, Inc. (FTH)vs › | $693.19M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $694.79M | -14.10% | -9.55% | -6.60% | -0.48% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $691.79M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $702.82M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | -1285.45% | -897.10% | -897.10% | -897.10% |
| Verastem, Inc. (VSTM)vs › | $681.02M | -547.98% | -848.64% | -1500.78% | -1508.87% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.65M | 52.93% | 53.31% | 49.89% | 44.80% |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 18.82% | 18.71% | 11.51% | 4.96% |
Gross Margin
79.3%
EBITDA Margin
-483.4%
Operating Margin
-504.1%
Net Margin
-309.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -3146.83% |
| 2026-03-31 | -75.81% |
| 2025-12-31 | -314.32% |
| 2025-09-30 | -711.40% |
| 2025-06-30 | -581.25% |
| 2025-03-31 | -519.24% |
| 2024-12-31 | 30.00% |
| 2024-09-30 | 804.55% |
| 2024-06-30 | -166.69% |
| 2024-03-31 | -257.47% |
| 2023-12-31 | -56.79% |
| 2023-09-30 | 11.46% |
| 2023-06-30 | -100.35% |
| 2023-03-31 | -223.16% |
| 2022-12-31 | -3393.95% |
| 2022-09-30 | -13074.39% |
| 2022-06-30 | -10791.73% |
| 2022-03-31 | -2077.94% |
| 2021-12-31 | -1945.10% |
| 2021-09-30 | -15.81% |
| 2021-06-30 | -1365.96% |
| 2020-12-31 | -299.78% |
| 2020-09-30 | -938.58% |
| 2020-06-30 | -1210.18% |
| 2020-03-31 | -1152.46% |
| 2019-12-31 | -2438.71% |
| 2019-09-30 | -1769.24% |
| 2019-06-30 | -568.54% |
| 2019-03-31 | -1514.34% |
| 2018-12-31 | -1304.67% |
| 2018-09-30 | -818.47% |
| 2018-06-30 | -724.31% |
| 2018-03-31 | -2433.19% |
| 2017-12-31 | -1771.54% |
| 2017-09-30 | -3904.88% |
| 2017-06-30 | -3659.47% |
| 2017-03-31 | -2899.26% |
| 2016-12-31 | -2698.96% |
| 2016-09-30 | -4348.21% |
| 2016-06-30 | -2746.76% |
| 2015-12-31 | -4659.21% |
| 2015-06-30 | -2809.52% |
| 2015-03-31 | -12984.62% |
